KERX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KERX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Keryx Biopharmaceuticals's adjusted free cash flow per share for the three months ended in Sep. 2018 was $-0.194. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2018.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
As of today (2024-05-05), Keryx Biopharmaceuticals's current stock price is $3.36. Keryx Biopharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2018 was $0.00. Keryx Biopharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Keryx Biopharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keryx Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Keryx Biopharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Keryx Biopharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Keryx Biopharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2018 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Sep. 2018 (Change) | * | Current CPI (Sep. 2018) |
= | -0.194 | / | 106.5067 | * | 106.5067 | |
= | -0.194 |
Current CPI (Sep. 2018) = 106.5067.
Keryx Biopharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
200812 | -0.072 | 88.697 | -0.086 |
200903 | -0.001 | 89.744 | -0.001 |
200906 | -0.041 | 91.003 | -0.048 |
200909 | 0.004 | 91.120 | 0.005 |
200912 | -0.065 | 91.111 | -0.076 |
201003 | -0.063 | 91.821 | -0.073 |
201006 | -0.058 | 91.962 | -0.067 |
201009 | -0.051 | 92.162 | -0.059 |
201012 | -0.101 | 92.474 | -0.116 |
201103 | -0.088 | 94.283 | -0.099 |
201106 | -0.041 | 95.235 | -0.046 |
201109 | -0.101 | 95.727 | -0.112 |
201112 | -0.107 | 95.213 | -0.120 |
201203 | -0.120 | 96.783 | -0.132 |
201206 | -0.053 | 96.819 | -0.058 |
201209 | -0.095 | 97.633 | -0.104 |
201212 | -0.077 | 96.871 | -0.085 |
201303 | -0.028 | 98.209 | -0.030 |
201306 | -0.089 | 98.518 | -0.096 |
201309 | -0.155 | 98.790 | -0.167 |
201312 | -0.152 | 98.326 | -0.165 |
201403 | -0.116 | 99.695 | -0.124 |
201406 | -0.198 | 100.560 | -0.210 |
201409 | -0.220 | 100.428 | -0.233 |
201412 | -0.368 | 99.070 | -0.396 |
201503 | -0.351 | 99.621 | -0.375 |
201506 | -0.372 | 100.684 | -0.394 |
201509 | -0.277 | 100.392 | -0.294 |
201512 | -0.256 | 99.792 | -0.273 |
201603 | -0.282 | 100.470 | -0.299 |
201606 | -0.141 | 101.688 | -0.148 |
201609 | -0.224 | 101.861 | -0.234 |
201612 | -0.192 | 101.863 | -0.201 |
201703 | -0.242 | 102.862 | -0.251 |
201706 | -0.162 | 103.349 | -0.167 |
201709 | -0.245 | 104.136 | -0.251 |
201712 | -0.169 | 104.011 | -0.173 |
201803 | -0.280 | 105.290 | -0.283 |
201806 | -0.177 | 106.317 | -0.177 |
201809 | -0.194 | 106.507 | -0.194 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott A Holmes | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210 |
Daniel Paul Regan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013 |
Jodie Pope Morrison | director, officer: Interim CEO | C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Mark J Enyedy | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Michael W Rogers | director | C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210 |
Baupost Group Gp, L.l.c. | 10 percent owner | 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
Baupost Group Llc/ma | director, 10 percent owner | 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
Seth A Klarman | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Greg Madison | director, officer: President and CEO | ONE MARINA PARK DRIVE LEXINGTON MA 02210 |
Brian Adams | officer: General Counsel and Secretary | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
John P. Butler | director | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
Sak Corp | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Oliviero James F Iii | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
From GuruFocus
By Marketwired Marketwired • 04-11-2018
By Holly LaFon Holly LaFon • 10-12-2015
By Marketwired Marketwired • 06-20-2018
By Bram de Haas Bram de Haas • 11-03-2015
By PRNewswire PRNewswire • 10-02-2018
By Marketwired Marketwired • 05-10-2018
By Marketwired Marketwired • 11-07-2018
By Jimmy Xiao gurujx • 03-24-2014
By Marketwired Marketwired • 08-08-2018